Tadalafil in the treatment of erectile dysfunction

References

• AlthofSECortyEWLevineSB1999EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunctionUrology53793910197859
   PubMed Web of Science ®Google Scholar
• BrigantiASaloniaAGallinaA2005Drug Insight: oral phospho-diesterase type 5 inhibitors for erectile dysfunctionNat Clin Pract Urol22394716474835
   PubMedGoogle Scholar
• BurnettALBivalacquaTJChampionHC2006Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapismUrology671043816698365
   PubMed Web of Science ®Google Scholar
• ButcherRWSutherlandEW1962Adenosine 3’,5’-phosphate in biological materials. I. Purification and properties of cyclic 30,50-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3’,5’-phosphate in human urineJ Biol Chem23712445013875173
   PubMed Web of Science ®Google Scholar
• BrockGBMcMahonCGChenKK2002aEfficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analysesJ Urol1681332612352386
   PubMed Web of Science ®Google Scholar
• BrockGMcMahonCPointP2002bEfficacy and safety of tadalafil in men with erectile dysfunction: an integrated analysis of registration trials [abstract]J Urol167178
   Web of Science ®Google Scholar
• CappelleriJCRosenRCSmithMD1999Diagnostic evaluation of the erectile function domain of the International Index of Erectile FunctionUrology543465110443736
   PubMed Web of Science ®Google Scholar
• CarsonCC2005Cardiac safety in clinical trials of phosphodiesterase 5 inhibitorsAm J Cardiol9637M41M
   PubMed Web of Science ®Google Scholar
• CarsonCC2007Phosphodiesterase type 5 inhibitors: state of the therapeutic classUrol Clin North Am345071517983891
   PubMed Web of Science ®Google Scholar
• CarsonCCGiulianoFGoldsteinI2004bThe ‘effectiveness’ scale – therapeutic outcome of pharmacologic therapies for ED: an international consensus panel reportInt J Impot Res162071315164088
   PubMed Web of Science ®Google Scholar
• CarsonCCHubbardJSWallenE2005bErectile dysfunction and treatment of carcinoma of the prostateCurr Urol Rep6461916238921
   PubMedGoogle Scholar
• CarsonCCLueTF2005Phosphodiesterase type 5 inhibitors for erectile dysfunctionBJU Int962578016042713
   PubMed Web of Science ®Google Scholar
• CarsonCCRajferJEardleyI2004aThe efficacy and safety of tadalafil: an updateBJU Int9312768115180622
   PubMed Web of Science ®Google Scholar
• CarsonCCShabsighRSegalS2005aEfficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centersUrology65353915708052
   PubMed Web of Science ®Google Scholar
• ConaglenHMConaglenJV2008Investigating women’s preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners’ preference studyJ Sex Med5119820718312284
   PubMed Web of Science ®Google Scholar
• CorbinJDFrancisSH2002Pharmacology of phosphodiesterase-5 inhibitorsInt J Clin Pract56453912166544
   PubMed Web of Science ®Google Scholar
• DeFrancesCJCullenKAKozakLJ2007National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure dataVital Health Stat131209
   Google Scholar
• De BerardisGPellegriniFFranciosiM2003Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factorsJ Urol1691422812629376
   PubMed Web of Science ®Google Scholar
• DeanRCLueTF2005Physiology of penile erection and pathophysiology of erectile dysfunctionUrol Clin North Am323799516291031
   PubMed Web of Science ®Google Scholar
• EardleyIMironeVMontorsiF2005An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapyBJU Int9613233216287454
   PubMed Web of Science ®Google Scholar
• FrancisSHCorbinJD2003Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonistsCurr Urol Rep44576514622499
   PubMedGoogle Scholar
• FrancisSHTurkoIVCorbinJD2001Cyclic nucleotide phosphodiesterases: relating structure and functionProg Nucleic Acid Res Mol Biol6515211008484
   PubMed Web of Science ®Google Scholar
• ForgueSTPattersonBEBeddingAW2006Tadalafil pharmacokinetics in healthy subjectsBr J Clin Pharmacol61280816487221
   PubMed Web of Science ®Google Scholar
• FonsecaVSeftelADenneJ2004Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trialsDiabetologia4719142315599697
   PubMed Web of Science ®Google Scholar
• GovierFPotempaAJKaufmanJ2003A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunctionClin Ther2527092314693299
   PubMed Web of Science ®Google Scholar
• GuptaMKovarAMeibohmB2005The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunctionJ Clin Pharmacol45987100316100293
   PubMed Web of Science ®Google Scholar
• Hanson-DiversCJacksonSELueTF1998Health outcomes variables important to patients in the treatment of erectile dysfunctionJ Urol159154179554350
   PubMed Web of Science ®Google Scholar
• HatzichristouDGamblaMRubio-AuriolesE2008Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunctionDiabet Med251384618290855
   PubMed Web of Science ®Google Scholar
• HellstromWJOverstreetJWYuA2003Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormonesJ Urol1708879112913723
   PubMed Web of Science ®Google Scholar
• HurtKJMusickiBPaleseMA2002Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erectionProc Natl Acad Sci U S A9940616611904450
   PubMed Web of Science ®Google Scholar
• ICOS2008Tadalafil (Cialis) US prescribing informationAccessed June 25, 2008. URL: http://www.lilly.com/us/cialis-pi.pdf
   Google Scholar
• IncrocciLSlagterCSlobAK2006A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinomaInt J Radiat Oncol Biol Phys664394416965992
   PubMed Web of Science ®Google Scholar
• IncrocciLSlobAKHopWC2007Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trialUrology701190318158045
   PubMed Web of Science ®Google Scholar
• JohannesCBAraujoABFeldmanHA2000Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging StudyJ Urol163460310647654
   PubMed Web of Science ®Google Scholar
• KaminetskyJ2008Epidemiology and pathophysiology of male sexual dysfunctionInt J Impot Res20S31018552831
   PubMed Web of Science ®Google Scholar
• KingSHHallockMStroteJ2005Tadalafil-associated priapismUrology6643216051318
   PubMed Web of Science ®Google Scholar
• KlonerRA2004Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunctionCirculation11031495515533876
   PubMed Web of Science ®Google Scholar
• KlonerRAHutterAMEmmickJT2003aTime course of the interaction between Tadalafil and NitratesJ Am Coll Cardiol42188560
   Web of Science ®Google Scholar
• KlonerRAJacksonGEmmickJT2004Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive menJ Urol17219354015540759
   PubMed Web of Science ®Google Scholar
• KlonerRAJacksonGHutterAM2006Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosingAm J Cardiol9717788416765134
   PubMed Web of Science ®Google Scholar
• KlonerRAMitchellMEmmickJT2003bCardiovascular effects of tadalafilAm J Cardiol9237M46M
   PubMed Web of Science ®Google Scholar
• KlonerRAMitchellMEmmickJT2003cCardiovascular effects of tadalafil in patients on common antihypertensive therapiesAm J Cardiol9247M57M
   PubMed Web of Science ®Google Scholar
• KostisJBJacksonGRosenR2005Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference)Am J Cardiol963132116018863
   PubMed Web of Science ®Google Scholar
• KovaneczIRambhatlaAFerriniMG2008Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resectionBJU Int1012031017888043
   PubMed Web of Science ®Google Scholar
• KraneRJWalshGittesPerlmutterStamey1986Sexual Function and DysfunctionCampbell’s Urology5th edPhiladelphiaW.B. Saunders Company1731
   Google Scholar
• LinCSXinZCLinG2003Phosphodiesterases as therapeutic targetsUrology616859112670544
   PubMed Web of Science ®Google Scholar
• LincolnTMCornwellTL1991Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxationBlood Vessels28129371848122
   PubMedGoogle Scholar
• LueTF2000Erectile dysfunctionN Engl J Med34218021310853004
   PubMed Web of Science ®Google Scholar
• McKinlayJB2000The worldwide prevalence and epidemiology of erectile dysfunctionInt J Impot Res12S6S1111035380
   PubMed Web of Science ®Google Scholar
• McMahonC2004Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafilJ Sex Med129230016422959
   PubMed Web of Science ®Google Scholar
• McMahonC2005Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunctionJ Sex Med24152516422874
   PubMed Web of Science ®Google Scholar
• McVaryKTMcKennaKE2004The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidenceCurr Urol Rep5251715260924
   PubMedGoogle Scholar
• McVaryKTRoehrbornCGKaminetskyJC2007Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasiaJ Urol1771401717382741
   PubMed Web of Science ®Google Scholar
• MenonMKaulSBhandariA2005Potency following robotic radical prostatectomy: a questionnaire based analysis of outcomes after conventional nerve sparing and prostatic fascia sparing techniquesJ Urol1742291616280816
   PubMed Web of Science ®Google Scholar
• MontorsiFBrockGLeeJ2008Effect of Nightly versus On-Demand Vardenafil on Recovery of Erectile Function in Men Following Bilateral Nerve-Sparing Radical ProstatectomyEur Urol79 [Epub ahead of print]
   Web of Science ®Google Scholar
• MontorsiFMcDermottTEMorganR1999Efficacy and safety of fixed-dose oral sildenafil in treatment of erectile dysfunction of various etiologiesUrology551011810223498
   PubMed Web of Science ®Google Scholar
• MontorsiFNathanHPMcCulloughA2004Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trialUrology172103641 Erratum in: J Urol, 2005;173:664
   Web of Science ®Google Scholar
• NIH Consensus Development Panel on Impotence1993NIH Consensus Conference: impotenceJAMA27083908510302
   PubMed Web of Science ®Google Scholar
• Padma-NathanHMcCulloughARLevineLA2008Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomyInt J Impot Res724 [Epub ahead of print]
   Web of Science ®Google Scholar
• PensonDFLatiniDMLubeckDP2003Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) databaseDiabetes Care261093912663579
   PubMed Web of Science ®Google Scholar
• PensonDFMcLerranDFengZ20085-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes StudyJ Urol179S40418405749
   PubMed Web of Science ®Google Scholar
• PorstHGiulianoFGlinaS2006Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trialEur Urol50351916766116
   PubMed Web of Science ®Google Scholar
• PorstHPadma-NathanHGiulianoF2003Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trialUrology62121512837435
   PubMed Web of Science ®Google Scholar
• PorstHRajferJCasabéA2008Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunctionJ Sex Med613 [Epub ahead of print]
   Web of Science ®Google Scholar
• PorstHRosenRCPadma-NathanH2002Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose [abstract]J Urol16717711743300
   PubMed Web of Science ®Google Scholar
• RainaRPahlajaniGAgarwalA2008Early penile rehabilitation following radical prostatectomy: Cleveland clinic experienceInt J Impot Res20121617687391
   PubMed Web of Science ®Google Scholar
• RajferJAliottaPJSteidleCP2007Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the USInt J Impot Res199510316871272
   PubMed Web of Science ®Google Scholar
• RambhatlaAKovaneczIFerriniM2008Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: experimental and clinical reviewInt J Impot Res2030417673932
   PubMed Web of Science ®Google Scholar
• RoehrbornCGMcVaryKTElion-MboussaA2008Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding studyJ Urol18012283418722631
   PubMed Web of Science ®Google Scholar
• RosenRCRileyAWagnerG1997The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunctionUrology49822309187685
   PubMed Web of Science ®Google Scholar
• Sáenz de TejadaIAnglinGKnightJR2002Effects of tadalafil on erectile dysfunction in men with diabetesDiabetes Care2521596412453954
   PubMed Web of Science ®Google Scholar
• StanfordJLFengJHamiltonAS2000Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes StudyJAMA2833546010647798
   PubMed Web of Science ®Google Scholar
• StröbergPMurphyACostiganT2003Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preferenceClin Ther2527243714693300
   PubMed Web of Science ®Google Scholar
• SutherlandEWRallTW1958Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particlesJ Biol Chem23210779113549488
   PubMed Web of Science ®Google Scholar
• TalcottJARiekerPPropertKJ1997Patient-reported impotence and incontinence after nerve-sparing radical prostatectomyJ Natl Cancer Inst891117239262249
   PubMed Web of Science ®Google Scholar
• UckertSKutheAJonasU2001Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostateJ Urol16624849011696815
   PubMed Web of Science ®Google Scholar
• VignozziLFilippiSMorelliA2006Effect of chronic tadalafil administration on penile hypoxia induced by cavernous neurotomy in the ratJ Sex Med34193116681467
   PubMed Web of Science ®Google Scholar
• von KeitzARajferJSegalS2004A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafilEur Urol4549950715041116
   PubMed Web of Science ®Google Scholar
• WalshPCLeporHEgglestonJC1983Radical prostatectomy with preservation of sexual function: anatomical and pathological considerationsProstate4473856889192
   PubMed Web of Science ®Google Scholar
• WalshPCMarschkePRickerD2000Patient-reported urinary continence and sexual function after anatomic radical prostatectomyUrology55586110654895
   PubMed Web of Science ®Google Scholar